Abvc biopharma, inc. reports strong q2 2024 financial results and strategic achievements

• executed global licensing agreements that could provide up to $292 million in income • received cash milestone incomes of $116,000 • achieved significant improvements in earnings • obtained multiple patents and fda approvals fremont, ca, aug. 15, 2024 (globe newswire) --   abvc biopharma, inc. (nasdaq: abvc), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, cns, and ophthalmology, is pleased to announce its financial results and key operational highlights for the second quarter ended june 30, 2024. key financial and operational highlights: 1.
ABVC Ratings Summary
ABVC Quant Ranking